Celltrion to supply rapid COVID-19 tests to US govt.

입력 2021. 9. 23. 16:45 수정 2021. 9. 23. 16:46
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

Celltrion's COVID-19 test kit DiaTrust (Celltrion)

Celltrion announced Thursday that it had won a contract to supply its rapid COVID-19 test DiaTrust to the US government.

Starting Oct. 1, Celltrion USA, Celltrion’s US-based unit, will begin supplying COVID-19 tests to 25,000 sites, including military facilities, nursing homes and COVID-19 test centers.

Under the deal signed with the US Defense Logistics Agency, the US authorities could buy more if needed. Celltrion said the total amount could reach 738.2 billion won ($626.61 million), without disclosing the initial order.

Bloomberg reported that the deal was for 19 million DiaTrust tests for $626.4 million.

Celltrion said among companies that recently won US government contracts, it expected to be the largest supplier of rapid COVID-19 tests.

“It is meaningful that the company has won the US government contract, which asks to procure domestic materials and products under the Buy American Act.”

Celltrion’s DiaTrust is an antigen test co-developed by Celltrion and local biotech firm Humasis. The test won emergency use authorization from the US Food and Drug Administration in April.

The rapid COVID-19 test, which is used in medical settings, can return results in about 15 minutes on-site.

By Shim Woo-hyun(ws@heraldcorp.com)

Copyrightⓒ Herald Media INC. All rights reserved.

이 기사에 대해 어떻게 생각하시나요?

이 뉴스에 대해 의견을 나눠보세요.
톡방 종료까지 00:00:00 남았습니다.

타임톡 참여하기